Neurol. pro Praxi, 2005; 6: 324-328

Časná stadia demence – možnosti diagnostiky a léčby

as. MUDr. Jakub Hort, Ph.D., MUDr. Martin Vyhnálek, doc. MUDr. Martin Bojar, CSc.
Neurologická klinika 2. LF UK a FN Motol, Praha

Většina pacientů s demencí není diagnostikována včas a řada z nich není zachycena vůbec. Rozvoj demence předchází mírná kognitivní porucha. V počátečních stadiích onemocnění se mohou velmi dobře uplatnit specializovaná vyšetření biomarkerů Alzheimerovy choroby a ostatních demencí a podrobné neuropsychologické vyšetření. Léčbou založenou na důkazech časných stadií demence jsou inhibitory acetylcholinesterázy, které se testovaly i u MCI. Čím dříve s léčbou začneme, tím se nám lépe daří oddálit nejzávažnější stadia onemocnění. Účinnost tradičně užívaných nootropik a vazoaktivních substancí není v případě Alzheimerovy choroby prokázána. Nezbytnou součástí péče je podpora duševní aktivity a sociálních vazeb pacientů.

Keywords: Klíčová slova: Alzheimerova choroba, mírná kognitivní porucha, časná diagnostika, biomarkery, léčba počátečních stadií demence.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hort J, Vyhnálek M, Bojar M. Časná stadia demence – možnosti diagnostiky a léčby. Neurol. praxi. 2005;6(6):324-328.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andreasen N, Vanmechelen E, Vanderstichele H, Davidson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and AB42 predicts development of Alzheimer´s disease in patients with mild cognitive impairment. Acta Neurol Scand 2003; 107 (Suppl 179): 47-51. Go to original source... Go to PubMed...
    2. Birks J, et al. Rivastigmine for Alzheimer´s disease (Cochrane Review). The Cochrane Library, Issue 2, 2002. Olin J, et al: Galantamine for Alzheimer´s disease (Cochrane Review), The Cochrane Library, Issue 2, 2002.Birks JS et al: Donepezil for mild and moderate Alzheimer´s disease (Cochrane Review).
    3. Busse, et al. Subclassifications for mild cognitive impairment: prevalence and predictive validity. Psychol Med 2003; 33: 1029-1038. Go to original source... Go to PubMed...
    4. Craig W, Rittchie MB, Ch.B., MRCPsych, M.Sc. David Ames,B.A., M.D., FRCPsych, FRANZCP Tim Clayton, M.Sc., Rosalind Lai, M.Lib.; Metaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine and Rivastigmine for the treatment of Alzheimer Disease. Am J Geriatr Psychiatry 12: 4, July August 2004. Go to original source...
    5. Cummings JL. Use of cholinesterase inhibitors in clinical practice. Am J Getriatr Psychiatry 2003; 11: 31-145. Go to original source...
    6. Doody RS. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry. 2003; 64 Suppl 9: 11-17.
    7. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology. 2001 May 8; 56(9): 1154-1166. Go to original source... Go to PubMed...
    8. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden (Eng). J Am Geriatr Soc 51(6): 737-44, Jun 2003. Go to original source... Go to PubMed...
    9. Grundman M, Petersen RC, et al. Mild cognitive impairment can be distinguished from Alzheimer Disease and normal aging for clinical trials. Arch Neurol. 2004; 61: 59-66. Go to original source... Go to PubMed...
    10. Jack CR, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000; 55: 484-489. Go to original source... Go to PubMed...
    11. Knopman DS, Petersen R: Clinical trials in dementia 1KP.003 - Educational Program Syllabus AAN 4/2005.
    12. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. Neurology 2000; 55: 1613-1620.
    13. NIA Consensus Report of the Working Group on:, ,Molecular and Biochemical Markers of Alzheimer's Disease" Neurobiol Aging 1998; 19: 109-116.
    14. Petersen, Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194. Go to original source... Go to PubMed...
    15. R.C. Petersen, R.G. Thomas et al for the ADCS Group: Vitamin E and Donepezil and for the Treatment of Mild Cognitive Impairment. The New England Journal of Medicine 2005; 352. Go to original source... Go to PubMed...
    16. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy od donepezil in early-stage Alzheimer disease. A randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852-1856. Go to original source... Go to PubMed...
    17. Summary of Product Characteristic: SPC Reminyl USA: www.fda.gov., SPC Aricept USA: www.fda.gov., SPC Exelon USA: www.fda.gov.
    18. P.N. Tariot, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 2004; 291: 317-324. Go to original source... Go to PubMed...
    19. Tariot PN, Doody RS, Peskind ER, Winblad B, Reisberg B, Stöffle rA, Graham SM, Jonas JM, McDonald S. Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary. Poster kongres CINP, Paříž, 2004. Go to original source...
    20. Tervo, et al. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord 2004; 17: 196-203. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.